All articles tagged with #boehringer ingelheim
The US FDA has approved Boehringer Ingelheim's drug Hernexeos for treating advanced non-squamous non-small cell lung cancer in patients who have previously received treatment, based on a study showing significant tumor reduction, with an accompanying diagnostic device approval for patient identification.
Boehringer Ingelheim and Zealand Pharma's drug, survodutide, has shown success in a Phase 2 study for the treatment of the liver condition MASH, with 83% of patients experiencing significant improvements compared to those who received a placebo. The study met its primary endpoint of improvements in MASH without the worsening of fibrosis, and secondary endpoints, including an improvement in fibrosis, were also achieved. This development comes amid increasing competition in the obesity medicine field.
Ginkgo Bioworks has partnered with Boehringer Ingelheim in a deal worth up to $406m, using its microbe-based database to find new molecules that the German pharma company could turn into new drugs. The deal includes upfront research and development fees, as well as payments based on hitting R&D, regulatory and commercial markers, and royalties on sales.
Ginkgo Bioworks has partnered with Boehringer Ingelheim to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery. The two companies will leverage Ginkgo's natural product discovery capabilities to mine Ginkgo's metagenomic sequence database, potentially enabling the rapid identification of lead molecules as starting points for the potential discovery of novel treatments to transform patients' lives.